

# Global VEGF Inhibitors Market Growth 2026-2032

<https://marketpublishers.com/r/GD3688E1244EEN.html>

Date: February 2026

Pages: 112

Price: US\$ 3,660.00 (Single User License)

ID: GD3688E1244EEN

## Abstracts

The global VEGF Inhibitors market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

Vascular endothelial growth factor inhibitors, are a class of medications that work by blocking the action of vascular endothelial growth factor (VEGF). VEGF is a protein that plays a crucial role in the formation of new blood vessels (angiogenesis) in both normal and pathological conditions, such as cancer. In medical practice, VEGF inhibitors are primarily used as anti-angiogenic agents to treat cancers and certain eye conditions.

United States market for VEGF Inhibitors is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for VEGF Inhibitors is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for VEGF Inhibitors is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key VEGF Inhibitors players cover Roche, Novartis, Coherus BioSciences, Bayer, Amneal Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the "VEGF Inhibitors Industry Forecast" looks at past sales and reviews total world VEGF Inhibitors sales in 2025, providing a comprehensive analysis by region and market sector of projected VEGF Inhibitors sales for 2026 through 2032. With VEGF Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world VEGF Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global VEGF Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on VEGF Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global VEGF Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for VEGF Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global VEGF Inhibitors.

This report presents a comprehensive overview, market shares, and growth opportunities of VEGF Inhibitors market by product type, application, key manufacturers and key regions and countries.

### **Segmentation by Type:**

Monoclonal Antibodies

Fusion Proteins

### **Segmentation by Application:**

Degenerative Eye Diseases

Cancer

Other

### **This report also splits the market by region:**

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Roche

Novartis

Coherus BioSciences

Bayer

Amneal Pharmaceuticals

Sanofi

Samsung Bioepis

Eli Lilly

Pfizer

Celltrion Healthcare

Amgen

Chengdu Kanghong Pharmaceutical

## **Key Questions Addressed in this Report**

What is the 10-year outlook for the global VEGF Inhibitors market?

What factors are driving VEGF Inhibitors market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do VEGF Inhibitors market opportunities vary by end market size?

How does VEGF Inhibitors break out by Type, by Application?

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### 2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
  - 2.1.1 Global VEGF Inhibitors Annual Sales 2021-2032
  - 2.1.2 World Current & Future Analysis for VEGF Inhibitors by Geographic Region, 2021, 2025 & 2032
  - 2.1.3 World Current & Future Analysis for VEGF Inhibitors by Country/Region, 2021, 2025 & 2032
- 2.2 VEGF Inhibitors Segment by Type
  - 2.2.1 Monoclonal Antibodies
  - 2.2.2 Fusion Proteins
  - 2.2.3 VEGF Inhibitors Sales by Type
    - 2.2.3.1 Global VEGF Inhibitors Sales Market Share by Type (2021-2026)
    - 2.2.3.2 Global VEGF Inhibitors Revenue and Market Share by Type (2021-2026)
    - 2.2.3.3 Global VEGF Inhibitors Sale Price by Type (2021-2026)
- 2.3 VEGF Inhibitors Segment by Application
  - 2.3.1 Degenerative Eye Diseases
  - 2.3.2 Cancer
  - 2.3.3 Other
  - 2.3.4 VEGF Inhibitors Sales by Application
    - 2.3.4.1 Global VEGF Inhibitors Sale Market Share by Application (2021-2026)
    - 2.3.4.2 Global VEGF Inhibitors Revenue and Market Share by Application (2021-2026)
    - 2.3.4.3 Global VEGF Inhibitors Sale Price by Application (2021-2026)

### 3 GLOBAL BY COMPANY

- 3.1 Global VEGF Inhibitors Breakdown Data by Company
  - 3.1.1 Global VEGF Inhibitors Annual Sales by Company (2021-2026)
  - 3.1.2 Global VEGF Inhibitors Sales Market Share by Company (2021-2026)
- 3.2 Global VEGF Inhibitors Annual Revenue by Company (2021-2026)
  - 3.2.1 Global VEGF Inhibitors Revenue by Company (2021-2026)
  - 3.2.2 Global VEGF Inhibitors Revenue Market Share by Company (2021-2026)
- 3.3 Global VEGF Inhibitors Sale Price by Company
- 3.4 Key Manufacturers VEGF Inhibitors Producing Area Distribution, Sales Area, Product Type
  - 3.4.1 Key Manufacturers VEGF Inhibitors Product Location Distribution
  - 3.4.2 Players VEGF Inhibitors Products Offered
- 3.5 Market Concentration Rate Analysis
  - 3.5.1 Competition Landscape Analysis
  - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
- 3.6 New Products and Potential Entrants
- 3.7 Market M&A Activity & Strategy

## **4 WORLD HISTORIC REVIEW FOR VEGF INHIBITORS BY GEOGRAPHIC REGION**

- 4.1 World Historic VEGF Inhibitors Market Size by Geographic Region (2021-2026)
  - 4.1.1 Global VEGF Inhibitors Annual Sales by Geographic Region (2021-2026)
  - 4.1.2 Global VEGF Inhibitors Annual Revenue by Geographic Region (2021-2026)
- 4.2 World Historic VEGF Inhibitors Market Size by Country/Region (2021-2026)
  - 4.2.1 Global VEGF Inhibitors Annual Sales by Country/Region (2021-2026)
  - 4.2.2 Global VEGF Inhibitors Annual Revenue by Country/Region (2021-2026)
- 4.3 Americas VEGF Inhibitors Sales Growth
- 4.4 APAC VEGF Inhibitors Sales Growth
- 4.5 Europe VEGF Inhibitors Sales Growth
- 4.6 Middle East & Africa VEGF Inhibitors Sales Growth

## **5 AMERICAS**

- 5.1 Americas VEGF Inhibitors Sales by Country
  - 5.1.1 Americas VEGF Inhibitors Sales by Country (2021-2026)
  - 5.1.2 Americas VEGF Inhibitors Revenue by Country (2021-2026)
- 5.2 Americas VEGF Inhibitors Sales by Type (2021-2026)
- 5.3 Americas VEGF Inhibitors Sales by Application (2021-2026)
- 5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

## **6 APAC**

6.1 APAC VEGF Inhibitors Sales by Region

6.1.1 APAC VEGF Inhibitors Sales by Region (2021-2026)

6.1.2 APAC VEGF Inhibitors Revenue by Region (2021-2026)

6.2 APAC VEGF Inhibitors Sales by Type (2021-2026)

6.3 APAC VEGF Inhibitors Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

## **7 EUROPE**

7.1 Europe VEGF Inhibitors by Country

7.1.1 Europe VEGF Inhibitors Sales by Country (2021-2026)

7.1.2 Europe VEGF Inhibitors Revenue by Country (2021-2026)

7.2 Europe VEGF Inhibitors Sales by Type (2021-2026)

7.3 Europe VEGF Inhibitors Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

## **8 MIDDLE EAST & AFRICA**

8.1 Middle East & Africa VEGF Inhibitors by Country

8.1.1 Middle East & Africa VEGF Inhibitors Sales by Country (2021-2026)

8.1.2 Middle East & Africa VEGF Inhibitors Revenue by Country (2021-2026)

8.2 Middle East & Africa VEGF Inhibitors Sales by Type (2021-2026)

8.3 Middle East & Africa VEGF Inhibitors Sales by Application (2021-2026)

- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

## **10 MANUFACTURING COST STRUCTURE ANALYSIS**

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of VEGF Inhibitors
- 10.3 Manufacturing Process Analysis of VEGF Inhibitors
- 10.4 Industry Chain Structure of VEGF Inhibitors

## **11 MARKETING, DISTRIBUTORS AND CUSTOMER**

- 11.1 Sales Channel
  - 11.1.1 Direct Channels
  - 11.1.2 Indirect Channels
- 11.2 VEGF Inhibitors Distributors
- 11.3 VEGF Inhibitors Customer

## **12 WORLD FORECAST REVIEW FOR VEGF INHIBITORS BY GEOGRAPHIC REGION**

- 12.1 Global VEGF Inhibitors Market Size Forecast by Region
  - 12.1.1 Global VEGF Inhibitors Forecast by Region (2027-2032)
  - 12.1.2 Global VEGF Inhibitors Annual Revenue Forecast by Region (2027-2032)
- 12.2 Americas Forecast by Country (2027-2032)
- 12.3 APAC Forecast by Region (2027-2032)
- 12.4 Europe Forecast by Country (2027-2032)
- 12.5 Middle East & Africa Forecast by Country (2027-2032)
- 12.6 Global VEGF Inhibitors Forecast by Type (2027-2032)
- 12.7 Global VEGF Inhibitors Forecast by Application (2027-2032)

## 13 KEY PLAYERS ANALYSIS

### 13.1 Roche

13.1.1 Roche Company Information

13.1.2 Roche VEGF Inhibitors Product Portfolios and Specifications

13.1.3 Roche VEGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Roche Main Business Overview

13.1.5 Roche Latest Developments

### 13.2 Novartis

13.2.1 Novartis Company Information

13.2.2 Novartis VEGF Inhibitors Product Portfolios and Specifications

13.2.3 Novartis VEGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Novartis Main Business Overview

13.2.5 Novartis Latest Developments

### 13.3 Coherus BioSciences

13.3.1 Coherus BioSciences Company Information

13.3.2 Coherus BioSciences VEGF Inhibitors Product Portfolios and Specifications

13.3.3 Coherus BioSciences VEGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 Coherus BioSciences Main Business Overview

13.3.5 Coherus BioSciences Latest Developments

### 13.4 Bayer

13.4.1 Bayer Company Information

13.4.2 Bayer VEGF Inhibitors Product Portfolios and Specifications

13.4.3 Bayer VEGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 Bayer Main Business Overview

13.4.5 Bayer Latest Developments

### 13.5 Amneal Pharmaceuticals

13.5.1 Amneal Pharmaceuticals Company Information

13.5.2 Amneal Pharmaceuticals VEGF Inhibitors Product Portfolios and Specifications

13.5.3 Amneal Pharmaceuticals VEGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 Amneal Pharmaceuticals Main Business Overview

13.5.5 Amneal Pharmaceuticals Latest Developments

### 13.6 Sanofi

13.6.1 Sanofi Company Information

13.6.2 Sanofi VEGF Inhibitors Product Portfolios and Specifications

13.6.3 Sanofi VEGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)

- 13.6.4 Sanofi Main Business Overview
- 13.6.5 Sanofi Latest Developments
- 13.7 Samsung Bioepis
  - 13.7.1 Samsung Bioepis Company Information
  - 13.7.2 Samsung Bioepis VEGF Inhibitors Product Portfolios and Specifications
  - 13.7.3 Samsung Bioepis VEGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.7.4 Samsung Bioepis Main Business Overview
  - 13.7.5 Samsung Bioepis Latest Developments
- 13.8 Eli Lilly
  - 13.8.1 Eli Lilly Company Information
  - 13.8.2 Eli Lilly VEGF Inhibitors Product Portfolios and Specifications
  - 13.8.3 Eli Lilly VEGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.8.4 Eli Lilly Main Business Overview
  - 13.8.5 Eli Lilly Latest Developments
- 13.9 Pfizer
  - 13.9.1 Pfizer Company Information
  - 13.9.2 Pfizer VEGF Inhibitors Product Portfolios and Specifications
  - 13.9.3 Pfizer VEGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.9.4 Pfizer Main Business Overview
  - 13.9.5 Pfizer Latest Developments
- 13.10 Celltrion Healthcare
  - 13.10.1 Celltrion Healthcare Company Information
  - 13.10.2 Celltrion Healthcare VEGF Inhibitors Product Portfolios and Specifications
  - 13.10.3 Celltrion Healthcare VEGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.10.4 Celltrion Healthcare Main Business Overview
  - 13.10.5 Celltrion Healthcare Latest Developments
- 13.11 Amgen
  - 13.11.1 Amgen Company Information
  - 13.11.2 Amgen VEGF Inhibitors Product Portfolios and Specifications
  - 13.11.3 Amgen VEGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.11.4 Amgen Main Business Overview
  - 13.11.5 Amgen Latest Developments
- 13.12 Chengdu Kanghong Pharmaceutical
  - 13.12.1 Chengdu Kanghong Pharmaceutical Company Information
  - 13.12.2 Chengdu Kanghong Pharmaceutical VEGF Inhibitors Product Portfolios and Specifications
  - 13.12.3 Chengdu Kanghong Pharmaceutical VEGF Inhibitors Sales, Revenue, Price

and Gross Margin (2021-2026)

13.12.4 Chengdu Kanghong Pharmaceutical Main Business Overview

13.12.5 Chengdu Kanghong Pharmaceutical Latest Developments

## **14 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

- Table 1. VEGF Inhibitors Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Table 2. VEGF Inhibitors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)
- Table 3. Major Players of Monoclonal Antibodies
- Table 4. Major Players of Fusion Proteins
- Table 5. Global VEGF Inhibitors Sales by Type (2021-2026) & (K Units)
- Table 6. Global VEGF Inhibitors Sales Market Share by Type (2021-2026)
- Table 7. Global VEGF Inhibitors Revenue by Type (2021-2026) & (\$ million)
- Table 8. Global VEGF Inhibitors Revenue Market Share by Type (2021-2026)
- Table 9. Global VEGF Inhibitors Sale Price by Type (2021-2026) & (US\$/Unit)
- Table 10. Global VEGF Inhibitors Sale by Application (2021-2026) & (K Units)
- Table 11. Global VEGF Inhibitors Sale Market Share by Application (2021-2026)
- Table 12. Global VEGF Inhibitors Revenue by Application (2021-2026) & (\$ million)
- Table 13. Global VEGF Inhibitors Revenue Market Share by Application (2021-2026)
- Table 14. Global VEGF Inhibitors Sale Price by Application (2021-2026) & (US\$/Unit)
- Table 15. Global VEGF Inhibitors Sales by Company (2021-2026) & (K Units)
- Table 16. Global VEGF Inhibitors Sales Market Share by Company (2021-2026)
- Table 17. Global VEGF Inhibitors Revenue by Company (2021-2026) & (\$ millions)
- Table 18. Global VEGF Inhibitors Revenue Market Share by Company (2021-2026)
- Table 19. Global VEGF Inhibitors Sale Price by Company (2021-2026) & (US\$/Unit)
- Table 20. Key Manufacturers VEGF Inhibitors Producing Area Distribution and Sales Area
- Table 21. Players VEGF Inhibitors Products Offered
- Table 22. VEGF Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
- Table 23. New Products and Potential Entrants
- Table 24. Market M&A Activity & Strategy
- Table 25. Global VEGF Inhibitors Sales by Geographic Region (2021-2026) & (K Units)
- Table 26. Global VEGF Inhibitors Sales Market Share Geographic Region (2021-2026)
- Table 27. Global VEGF Inhibitors Revenue by Geographic Region (2021-2026) & (\$ millions)
- Table 28. Global VEGF Inhibitors Revenue Market Share by Geographic Region (2021-2026)
- Table 29. Global VEGF Inhibitors Sales by Country/Region (2021-2026) & (K Units)
- Table 30. Global VEGF Inhibitors Sales Market Share by Country/Region (2021-2026)

Table 31. Global VEGF Inhibitors Revenue by Country/Region (2021-2026) & (\$ millions)

Table 32. Global VEGF Inhibitors Revenue Market Share by Country/Region (2021-2026)

Table 33. Americas VEGF Inhibitors Sales by Country (2021-2026) & (K Units)

Table 34. Americas VEGF Inhibitors Sales Market Share by Country (2021-2026)

Table 35. Americas VEGF Inhibitors Revenue by Country (2021-2026) & (\$ millions)

Table 36. Americas VEGF Inhibitors Sales by Type (2021-2026) & (K Units)

Table 37. Americas VEGF Inhibitors Sales by Application (2021-2026) & (K Units)

Table 38. APAC VEGF Inhibitors Sales by Region (2021-2026) & (K Units)

Table 39. APAC VEGF Inhibitors Sales Market Share by Region (2021-2026)

Table 40. APAC VEGF Inhibitors Revenue by Region (2021-2026) & (\$ millions)

Table 41. APAC VEGF Inhibitors Sales by Type (2021-2026) & (K Units)

Table 42. APAC VEGF Inhibitors Sales by Application (2021-2026) & (K Units)

Table 43. Europe VEGF Inhibitors Sales by Country (2021-2026) & (K Units)

Table 44. Europe VEGF Inhibitors Revenue by Country (2021-2026) & (\$ millions)

Table 45. Europe VEGF Inhibitors Sales by Type (2021-2026) & (K Units)

Table 46. Europe VEGF Inhibitors Sales by Application (2021-2026) & (K Units)

Table 47. Middle East & Africa VEGF Inhibitors Sales by Country (2021-2026) & (K Units)

Table 48. Middle East & Africa VEGF Inhibitors Revenue Market Share by Country (2021-2026)

Table 49. Middle East & Africa VEGF Inhibitors Sales by Type (2021-2026) & (K Units)

Table 50. Middle East & Africa VEGF Inhibitors Sales by Application (2021-2026) & (K Units)

Table 51. Key Market Drivers & Growth Opportunities of VEGF Inhibitors

Table 52. Key Market Challenges & Risks of VEGF Inhibitors

Table 53. Key Industry Trends of VEGF Inhibitors

Table 54. VEGF Inhibitors Raw Material

Table 55. Key Suppliers of Raw Materials

Table 56. VEGF Inhibitors Distributors List

Table 57. VEGF Inhibitors Customer List

Table 58. Global VEGF Inhibitors Sales Forecast by Region (2027-2032) & (K Units)

Table 59. Global VEGF Inhibitors Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 60. Americas VEGF Inhibitors Sales Forecast by Country (2027-2032) & (K Units)

Table 61. Americas VEGF Inhibitors Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 62. APAC VEGF Inhibitors Sales Forecast by Region (2027-2032) & (K Units)

Table 63. APAC VEGF Inhibitors Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 64. Europe VEGF Inhibitors Sales Forecast by Country (2027-2032) & (K Units)

Table 65. Europe VEGF Inhibitors Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 66. Middle East & Africa VEGF Inhibitors Sales Forecast by Country (2027-2032) & (K Units)

Table 67. Middle East & Africa VEGF Inhibitors Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 68. Global VEGF Inhibitors Sales Forecast by Type (2027-2032) & (K Units)

Table 69. Global VEGF Inhibitors Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 70. Global VEGF Inhibitors Sales Forecast by Application (2027-2032) & (K Units)

Table 71. Global VEGF Inhibitors Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 72. Roche Basic Information, VEGF Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 73. Roche VEGF Inhibitors Product Portfolios and Specifications

Table 74. Roche VEGF Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 75. Roche Main Business

Table 76. Roche Latest Developments

Table 77. Novartis Basic Information, VEGF Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 78. Novartis VEGF Inhibitors Product Portfolios and Specifications

Table 79. Novartis VEGF Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 80. Novartis Main Business

Table 81. Novartis Latest Developments

Table 82. Coherus BioSciences Basic Information, VEGF Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 83. Coherus BioSciences VEGF Inhibitors Product Portfolios and Specifications

Table 84. Coherus BioSciences VEGF Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 85. Coherus BioSciences Main Business

Table 86. Coherus BioSciences Latest Developments

Table 87. Bayer Basic Information, VEGF Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 88. Bayer VEGF Inhibitors Product Portfolios and Specifications

Table 89. Bayer VEGF Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit)

and Gross Margin (2021-2026)

Table 90. Bayer Main Business

Table 91. Bayer Latest Developments

Table 92. Amneal Pharmaceuticals Basic Information, VEGF Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 93. Amneal Pharmaceuticals VEGF Inhibitors Product Portfolios and Specifications

Table 94. Amneal Pharmaceuticals VEGF Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 95. Amneal Pharmaceuticals Main Business

Table 96. Amneal Pharmaceuticals Latest Developments

Table 97. Sanofi Basic Information, VEGF Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 98. Sanofi VEGF Inhibitors Product Portfolios and Specifications

Table 99. Sanofi VEGF Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 100. Sanofi Main Business

Table 101. Sanofi Latest Developments

Table 102. Samsung Bioepis Basic Information, VEGF Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 103. Samsung Bioepis VEGF Inhibitors Product Portfolios and Specifications

Table 104. Samsung Bioepis VEGF Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 105. Samsung Bioepis Main Business

Table 106. Samsung Bioepis Latest Developments

Table 107. Eli Lilly Basic Information, VEGF Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 108. Eli Lilly VEGF Inhibitors Product Portfolios and Specifications

Table 109. Eli Lilly VEGF Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 110. Eli Lilly Main Business

Table 111. Eli Lilly Latest Developments

Table 112. Pfizer Basic Information, VEGF Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 113. Pfizer VEGF Inhibitors Product Portfolios and Specifications

Table 114. Pfizer VEGF Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 115. Pfizer Main Business

Table 116. Pfizer Latest Developments

Table 117. Celltrion Healthcare Basic Information, VEGF Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 118. Celltrion Healthcare VEGF Inhibitors Product Portfolios and Specifications

Table 119. Celltrion Healthcare VEGF Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 120. Celltrion Healthcare Main Business

Table 121. Celltrion Healthcare Latest Developments

Table 122. Amgen Basic Information, VEGF Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 123. Amgen VEGF Inhibitors Product Portfolios and Specifications

Table 124. Amgen VEGF Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 125. Amgen Main Business

Table 126. Amgen Latest Developments

Table 127. Chengdu Kanghong Pharmaceutical Basic Information, VEGF Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 128. Chengdu Kanghong Pharmaceutical VEGF Inhibitors Product Portfolios and Specifications

Table 129. Chengdu Kanghong Pharmaceutical VEGF Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 130. Chengdu Kanghong Pharmaceutical Main Business

Table 131. Chengdu Kanghong Pharmaceutical Latest Developments

## List Of Figures

### LIST OF FIGURES

- Figure 1. Picture of VEGF Inhibitors
- Figure 2. VEGF Inhibitors Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global VEGF Inhibitors Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global VEGF Inhibitors Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. VEGF Inhibitors Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. VEGF Inhibitors Sales Market Share by Country/Region (2025)
- Figure 10. VEGF Inhibitors Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Monoclonal Antibodies
- Figure 12. Product Picture of Fusion Proteins
- Figure 13. Global VEGF Inhibitors Sales Market Share by Type in 2026
- Figure 14. Global VEGF Inhibitors Revenue Market Share by Type (2021-2026)
- Figure 15. VEGF Inhibitors Consumed in Degenerative Eye Diseases
- Figure 16. Global VEGF Inhibitors Market: Degenerative Eye Diseases (2021-2026) & (K Units)
- Figure 17. VEGF Inhibitors Consumed in Cancer
- Figure 18. Global VEGF Inhibitors Market: Cancer (2021-2026) & (K Units)
- Figure 19. VEGF Inhibitors Consumed in Other
- Figure 20. Global VEGF Inhibitors Market: Other (2021-2026) & (K Units)
- Figure 21. Global VEGF Inhibitors Sale Market Share by Application (2025)
- Figure 22. Global VEGF Inhibitors Revenue Market Share by Application in 2026
- Figure 23. VEGF Inhibitors Sales by Company in 2026 (K Units)
- Figure 24. Global VEGF Inhibitors Sales Market Share by Company in 2026
- Figure 25. VEGF Inhibitors Revenue by Company in 2026 (\$ millions)
- Figure 26. Global VEGF Inhibitors Revenue Market Share by Company in 2026
- Figure 27. Global VEGF Inhibitors Sales Market Share by Geographic Region (2021-2026)
- Figure 28. Global VEGF Inhibitors Revenue Market Share by Geographic Region in 2026
- Figure 29. Americas VEGF Inhibitors Sales 2021-2026 (K Units)
- Figure 30. Americas VEGF Inhibitors Revenue 2021-2026 (\$ millions)
- Figure 31. APAC VEGF Inhibitors Sales 2021-2026 (K Units)

- Figure 32. APAC VEGF Inhibitors Revenue 2021-2026 (\$ millions)
- Figure 33. Europe VEGF Inhibitors Sales 2021-2026 (K Units)
- Figure 34. Europe VEGF Inhibitors Revenue 2021-2026 (\$ millions)
- Figure 35. Middle East & Africa VEGF Inhibitors Sales 2021-2026 (K Units)
- Figure 36. Middle East & Africa VEGF Inhibitors Revenue 2021-2026 (\$ millions)
- Figure 37. Americas VEGF Inhibitors Sales Market Share by Country in 2026
- Figure 38. Americas VEGF Inhibitors Revenue Market Share by Country (2021-2026)
- Figure 39. Americas VEGF Inhibitors Sales Market Share by Type (2021-2026)
- Figure 40. Americas VEGF Inhibitors Sales Market Share by Application (2021-2026)
- Figure 41. United States VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 42. Canada VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 43. Mexico VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 44. Brazil VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 45. APAC VEGF Inhibitors Sales Market Share by Region in 2026
- Figure 46. APAC VEGF Inhibitors Revenue Market Share by Region (2021-2026)
- Figure 47. APAC VEGF Inhibitors Sales Market Share by Type (2021-2026)
- Figure 48. APAC VEGF Inhibitors Sales Market Share by Application (2021-2026)
- Figure 49. China VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 50. Japan VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 51. South Korea VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 52. Southeast Asia VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 53. India VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 54. Australia VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 55. China Taiwan VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 56. Europe VEGF Inhibitors Sales Market Share by Country in 2026
- Figure 57. Europe VEGF Inhibitors Revenue Market Share by Country (2021-2026)
- Figure 58. Europe VEGF Inhibitors Sales Market Share by Type (2021-2026)
- Figure 59. Europe VEGF Inhibitors Sales Market Share by Application (2021-2026)
- Figure 60. Germany VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 61. France VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 62. UK VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 63. Italy VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 64. Russia VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 65. Middle East & Africa VEGF Inhibitors Sales Market Share by Country (2021-2026)
- Figure 66. Middle East & Africa VEGF Inhibitors Sales Market Share by Type (2021-2026)
- Figure 67. Middle East & Africa VEGF Inhibitors Sales Market Share by Application (2021-2026)

- Figure 68. Egypt VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 69. South Africa VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 70. Israel VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 71. Turkey VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 72. GCC Countries VEGF Inhibitors Revenue Growth 2021-2026 (\$ millions)
- Figure 73. Manufacturing Cost Structure Analysis of VEGF Inhibitors in 2026
- Figure 74. Manufacturing Process Analysis of VEGF Inhibitors
- Figure 75. Industry Chain Structure of VEGF Inhibitors
- Figure 76. Channels of Distribution
- Figure 77. Global VEGF Inhibitors Sales Market Forecast by Region (2027-2032)
- Figure 78. Global VEGF Inhibitors Revenue Market Share Forecast by Region (2027-2032)
- Figure 79. Global VEGF Inhibitors Sales Market Share Forecast by Type (2027-2032)
- Figure 80. Global VEGF Inhibitors Revenue Market Share Forecast by Type (2027-2032)
- Figure 81. Global VEGF Inhibitors Sales Market Share Forecast by Application (2027-2032)
- Figure 82. Global VEGF Inhibitors Revenue Market Share Forecast by Application (2027-2032)

## I would like to order

Product name: Global VEGF Inhibitors Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/GD3688E1244EEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD3688E1244EEN.html>